Non-Alcoholic Steato-Hepatitis (NASH) Research Study
Research Centre: Scientia Clinical Research Ltd
Location: 5 Bright Building Corner High, Avoca St, Randwick NSW 2031, Australia
Lead Doctor: Professor Stephen Riordan
Ethics Committee: This study has been reviewed and approved by the Bellberry Human Research Ethics Committee
NASH is a form of non-alcoholic fatty liver disease and is the most common chronic liver disorder. Patients with NASH have a build up of fat in the liver and have an inflammation of the liver, called hepatitis. Inflammation and liver cell damage can cause fibrosis, or scarring, of the liver, which may progress to cirrhosis and liver cancer. Currently there is no registered drug therapy exists for this disease.
The purpose of this study is to determine how safe and well tolerated the study treatment is in people with NASH.
This study seeks men and women who currently suffer from Non-Alcoholic Steato-Hepatitis (NASH). Participants are required to attend 1 screening visit, a 9-consecutive night overnight study visit (you cannot leave during this time) and 1 follow-up visit over a 2 month period and will be compensated $3100 for participating in this study.
- You will be contributing to a potential new treatment that may help NASH patients by slowing liver disease progression and decreasing the need for liver transplant.
- You will be compensated $3100 for participating in this study.
- You will be helping to advance medical research.
- If you decide to participate in the study and later feel that you no longer wish to be part of it, you may withdraw at any time.
- Your records relating to this study and any other information received will be kept strictly confidential, except as required by the law.
- Qualified health professionals will monitor your health as it relates to the study.
Who Can Participate?
- Men and women aged 18-70 who suffer from Non-Alcoholic Steato-Hepatitis (NASH)
- Have not had surgery in the past month
- Able to attend 1 screening visit, a 9-consecutive night overnight study visit (you cannot leave during this time) and 1 follow-up visit over a 2 month period